Rebyota is a fecal microbiota live-jslm product approved by the FDA for preventing recurrent C. diff infection in the form of a single 150 mL dose administered rectally. Data from more than 1,500 ...

Cases of a potentially killer infection that can spread rampantly in hospitals have surged by a third in a year, health officials have warned. Clostridioides difficile, commonly referred to as C.

RBX2660 has been granted Orphan Drug status, Fast Track status and gained Breakthrough Therapy Designation from the FDA in October 2015 for its potential to prevent recurrent C. diff. infection.

SAN DIEGO — Administration of Rebyota by colonoscopy appears safe and effective among adults with recurrent Clostridioides difficile infection ... data for recurrent C. diff patients receiving ...

diff can be life-threatening. In many instances, cases of C. diff occur after a person has taken a course of antibiotics. According to researchers, the infection is lethal in about 6% of cases in the ...

Apr. 9, 2025 — A new study has found that certain bacteria living in the nose may influence how likely someone is to get a COVID-19 infection ... 2025 — C. difficile (C. diff) is one of ...

Mild Clostridium difficile infection (CDI; stool frequency <four-times daily; no signs of severe colitis), clearly induced by the use of antibiotics, may be treated by stopping the inducing ...